ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	2.62B
Revenue (ttm)	813.81M
Net Income (ttm)	-1.71M
Shares Out	165.22M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	20.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	884,068
Open	16.30
Previous Close	16.04
Day's Range	15.75 - 16.43
52-Week Range	14.55 - 33.99
Beta	0.40
Analysts	Buy
Price Target	29.40 (+85.61%)
Earnings Date	Jul 31, 2024

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 598
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD

Financial Performance

In 2023, ACAD's revenue was $726.44 million, an increase of 40.45% compared to the previous year's $517.24 million. Losses were -$61.29 million, -71.62% less than in 2022.

Analyst Forecast

According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $29.4, which is an increase of 85.61% from the latest price.

Price Target

$29.4

(85.61% upside)

Analyst Consensus: Buy